Harmeet Singh

Harmeet Singh

Auto-generated profile, based on publicly available information

Harmeet Singh

PCTE Group of Institutes

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2021 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
TATamanna
Tamanna
HSHarmeet Singh
Harmeet Singh
Skin, the integument system; pertaining to our body which consists of mainly three layers (i) Epidermis (ii) Dermis (iii) Subcutaneous Tissue. It acts as a protective barrier against many diseases and infections. Skin disorders vary greatly in symptoms and severity. Some may be attributed to situational causes while others may be genetic like atopic dermatitis, melanoma, acne vulgaris, wound healing and psoriasis. Conventional therapies are used to analyze various topical disorders suffers from many limitations i.e. less efficacy, poor patient compliance, and poor bioavailability. Therefore, novel approaches should be investigated for the development of better treatment of the disease. Novel carriers such as Liposome, Niosomes, Ethosomes, Silver nanoparticles, Solid lipid nanoparticles are utilized through almost all the routes of administration to treat dermatological disorders. These Nano systems are used to provide targeted drug delivery and a site-specific delivery of dosage form at a particular receptor site and thus enhance the uptake of poorly soluble drugs and overcome the issues related to poor bioavailability. The root cause for the development of such carriers lies on making the existing drugs more effective and safe for the patients. Keywords: Skin, Skin disorders, NDDS, Novel Carriers, Nanotechnology

1 October 2009 in Journal of Nanoscience and Nanotechnology
Verified
Journal Article
Closed access
SBS. V. Bhagwat
S. V. Bhagwat
SJS. Jouen
S. Jouen
DKD. C. Kundaliya
D. C. Kundaliya
HSH. Singh
H. Singh
TJT. Jagadale
T. Jagadale
SOS. B. Ogale
S. B. Ogale
Anisotropic growth of magnetite (Fe3O4) nanoparticles is achieved in a hydrothermal growth process using hexamine to play a dual role of oxide forming and directing agent. The samples are characterized by X-ray diffraction, scanning electron microscopy, high resolution transmission electron microscopy, squid magnetometry, ferromagnetic resonance technique, diffuse reflectance spectroscopy and Mössbauer spectroscopy, which collectively establish the formation of Fe3O4 phase. Anisotropic structures such as nanorods and nanotubules are revealed and these are shown to exhibit good humidity sensing properties.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
JSJagtar Singh
Jagtar Singh
MSMohit Sharma
Mohit Sharma
AMAmit Mittal
Amit Mittal
PUPuneet Utreja
Puneet Utreja
HSHarmeet Singh
Harmeet Singh
SKShubham Kumar
Shubham Kumar
Background: Mesalamine, an anti-inflammatory drug, is a first-line drug used in the treatment of ulcerative colitis. The premature release of drugs associated with the marketed formulations causes side effects like gastric trouble, nausea, vomiting, diarrhea, etc. These systemic side effects can be minimized by ensuring the site-specific and local delivery of the drug to the colon. Also, the pharmacotherapeutic role of the gut microbiome has a significant impact on the remission of ulcerative colitis. These probiotics being acid-labile necessitates developing a gastro-resistant formulation that can enhance the delivery of viable cells at the site of inflammation. Aim and Objectives: The present study was aimed at developing colon-targeted hydrogel beads loaded with mesalamine and Bifidobacterium bifidum for their synergistic role in the long-term management of ulcerative colitis. This co-encapsulated formulation is target specific, increases the residence time of the drug in the colon due to mucoadhesiveness, sustains the release profile, and significantly enhances the cell viability for better colonization in the colonic mucosa. Methods: The mesalamine and Bifidobacterium bifidum loaded hydrogel beads were prepared by ionotropic gelation. The effect of single and dual cross-linking approach on various formulation characteristics was studied. Eudragit ® S100 gastro-resistant capsules were prepared in standard size 00. The optimised formulation was filled inside the Eudragit ® capsules. Results There was no potential interaction between the drug and the polymer, confirmed through FTIR analysis. The mean particle size, angle of repose, percentage yield, drug entrapment efficiency, percentage drug loading, cell entrapment efficiency, swelling index, mucoadhesiveness, disintegration time (for capsules), and in vitro dissolution profile of the optimized formulation was found to be 457.3±12.5µm, 25.51±0.57, 98.75±0.6%, 98.4±2.56%, 49.8±0.64%, 81.03±2.57%, 10.41±2.02, 83.1±3.62, 12 minutes 46 seconds and 99.85±1.07% (in 20 hours) respectively. All the values were statistically significant at p<0.05. Conclusion: The results strongly supported the aim of the study that prepared hydrogel beads can release mesalamine at colonic pH in a sustained manner while significantly increasing the delivery of viable cells to the colon.